NCT03722147View on ClinicalTrials.gov

A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

August 13, 2018

Primary Completion Date

January 10, 2020

Study Completion Date

December 31, 2021

Conditions
Hodgkin's Lymphoma
Interventions
BIOLOGICAL

AK105

AK105 200 mg intravenously (IV) every-2-weeks (Q2W)

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY